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Leading in education, therapeutic 
approaches, and innovative research
DIVISION OF RHEUMATOLOGY
A message from the Chief
Leading in education, therapeutic 
approaches, and innovative research
The UNMC Division of Rheumatology is recognized both nationally and internationally as a 
leader in innovative treatments for rheumatoid arthritis, for outcomes and database research 
and for treatments of gout. Further, the division has an unparalleled record of educating 
fellows, residents and students on the rheumatic diseases. Our mission is to continue pursuing 
ground breaking approaches in research, clinical care and education in rheumatic diseases. 
UNMC researchers have made major contributions to rheumatology through the conduct of 
investigator-initiated clinical trials in The Rheumatology and Arthritis Investigational Network 
(RAIN) over the past two decades. RAIN is recognized internationally as the largest network of its 
kind in the United States that specializes in RA investigator-initiated clinical research. The RAIN 
network was responsible for multiple innovative studies including the initial trial and subsequent 
worldwide prominence of “Triple Therapy” in the management of rheumatoid arthritis (NEJM 1996).
The Nebraska Arthritis Outcomes Research Center (NAORC) was established in 
2007 by the generous donation by Ruth and Bill Scott and represents a collaborative 
effort of our division with the UNMC Department of Orthopaedics. 
Researchers from the Division of Rheumatology, in efforts both at UNMC and the Omaha VA Medical 
Center, actively collaborate on a national and international level to address important clinical questions:
1. NAORC researchers recently conducted the largest study ever demonstrating an 
association between gum disease and the risk of developing rheumatoid arthritis. The 
results suggest that treatments aimed at gum disease could play an important role 
in arthritis treatment and prevention. This study involved investigators at UNMC and 
VA medical centers in Omaha, Dallas, Washington and Salt Lake City. This work has 
led to collaborations with investigators from across the U.S. and in Europe. 
2. The multicenter, multi-national Rheumatoid Arthritis Comparison of Active Therapies (RACAT) 
study was led by our division at the Omaha VA and UNMC and included NAORC investigators. 
The study, published as the lead article in the July 25, 2013 issue of the New England Journal 
of Medicine, demonstrated clearly that a combination of conventional generic medications 
(Triple Therapy) works as well as newer, more expensive biologic medicines in the treatment of 
rheumatoid arthritis. Thus, providing the potential of huge cost savings without sacrificing quality.
3. Another national program directed by our division is the Veteran Affairs Rheumatoid 
Arthritis (VARA) registry created more than 10 years ago. This registry is the largest 
and best characterized, predominantly male RA cohort in the world. VARA, in addition 
to Omaha, now includes enrollment sites at 11 VA medical centers across the country 
including those located in Birmingham, Brooklyn, Dallas, Denver, Iowa City, Jackson, 
Little Rock, Portland, Philadelphia, Salt Lake City and Washington, D.C. 
We strive to provide exceptional comprehensive clinical care. For example, UNMC is a leader in 
musculoskeletal ultrasound. This valuable tool provides physicians with better information about the 
conditions they treat. Future rheumatologists are educated through the fellowship program in the 
Division of Rheumatology. Our fellows have a perfect 100 percent pass rate on rheumatology boards 
for the entire history of our program. Our residents and fellows frequently have the opportunity to 
participate in research and present at the annual American College of Rheumatology conference. 
Current advances in rheumatology and exciting and promising avenues make rheumatology 
a vibrant and growing one. UNMC’s Division of Rheumatology is proud to have the 
people, programs and cutting-edge research projects to participate in these advances, 
helping position the division to support our patients and those around the world.
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Nebraska Arthritis 
Outcomes Research Center 
puts UNMC on cutting edge
Center’s Opening a great milestone 
for research, education at UNMC. 
Medical education:              
A fresh perspective
Amy Cannella, MD, MPH, sees exciting 
new educational opportunities 
for students and fellows. 
The reader
Alan Erickson, MD, serves as 
an “expert reader” of films for 
the Rheumatology division.
Lupus study becomes 
international affair
Dr. Michelene Hearth-Holmes’ 
collaboration expands the 
demographics of the RAIN database.
The puzzle of ‘the loss  
of self-tolerance’
Lynell Klassen, MD, has spent a career 
grappling with one question: Why do 
people react to their own tissue? 
An icon in rheumatology
A superlative internist, Dr. Gerald Moore’s 
biggest impact may be his legacy of 
committed and talented students.
Registry, research
offer insights into 
RA risk factors
Ted Mikuls, MD, MSPH, is spearheading 
two efforts aimed at helping 
rheumatoid arthritis sufferers.
On the RISE
Kaleb Michaud, PhD, is helping 
use technology and databases 
to better serve RA patients.
RAIN man
Dr. James O’Dell and the Rheumatology 
and Arthritis Investigational 
Network have led UNMC to an 
international profile in RA research.
A top-tier team player
Dr. Geoffrey Thiele’s cross-
departmental collaborations link RA 
research with other disciplines.













The Division of Rheumatology is a national and international leader in 
the diagnosis and treatment of diseases that affect the joints, connective 
tissue diseases, and autoimmune diseases. We are pursuing state-of-
the-art approaches in research, clinical care, and education programs 
in rheumatic diseases, with areas of expertise to include rheumatoid 
arthritis, osteoarthritis, granulomatosis with polyangiitis, gout and 
systemic lupus erythematosus. Private donations have led to the founding 
of the Nebraska Arthritis Outcomes Research Center (NAORC), have 
directly supported the world renowned Rheumatology and Arthritis 
Investigational Network (RAIN), and have allowed us to lead research 
efforts devoted to improving the quality of life for our patients.
From left, Alan Erickson, MD, Amy Cannella, MD, MS, Gerald Moore, MD, James O’Dell, MD, 
Lynell Klassen, MD, Ted Mikuls, MD, MSPH, and Michelene Hearth-Holmes, MD, MEd
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Nebraska Arthritis Outcomes Research 
Center puts UNMC on cutting edge
links between investigators across our campus 
and across the U.S., all with the common goal of 
improving outcomes for our arthritis patients,” 
said Dr. Mikuls. “Our collaborations have led 
to important work in several areas and now 
includes active and highly productive work 
with investigators from the Colleges of Public 
Health, Pharmacy, and Dentistry among others.”
Since its inception in 2007, NAORC has 
made substantial progress in research 
focused on gaining a better understanding 
of arthritis risk, its impact on patients and 
the best treatment strategies. In addition to 
leading cutting edge research programs and 
supported in large part by initial NAORC 
funding, center faculty members have: 
• expanded the center’s reach both 
nationally and internationally; 
• grown the research infrastructure 
at UNMC and the Omaha VA for 
arthritis-focused investigations;
• trained the next generation of 
arthritis researchers; and 
• developed a strong publication portfolio.
NAORC’s goals over the next five years are to 
continue to expand these efforts with targeted, 
strategic faculty recruitments and expansion 
of currently available infrastructure supporting 
clinical and translational arthritis research.
N A O R C  A C C O M P L I S H M E N T S 
S I N C E  2 0 07  I N C L U D E :
Cutting Edge Research
• The Treatment of Rheumatoid Arthritis 
The multicenter, multinational RACAT study 
was led by Omaha VA and UNMC NAORC 
investigators. Recently published in the New 
England Journal of Medicine (July 2013) and 
receiving national media attention, the study 
showed that a combination of conventional 
generic medications works as well as 
newer, more expensive biologic medicines 
in the treatment of rheumatoid arthritis.
• Novel Methods of Drug Delivery in Arthritis 
NAORC research efforts have led to highly 
innovative strategies of selectively delivering 
arthritis treatments to the inflamed joint. 
By targeting (and limiting) drug delivery 
to the diseased joint, these new treatment 
approaches hold substantial promise in 
limiting common drug-related toxicities that 
complicate arthritis management. Pilot studies 
In July 2007, the Nebraska Arthritis Outcomes 
Research Center (NAORC), a collaborative 
effort of the Division of Rheumatology and 
the Department of Orthopaedics, was 
established on the UNMC campus.
The center, under the direction of Ted 
Mikuls, MD, MSPH, and Kaleb Michaud, 
PhD, conducts studies to better understand 
the development of arthritis and predict 
outcomes. The center was made possible by 
a major donation by Ruth and Bill Scott.
The opening of NAORC was a great milestone 
for research and education in the Rheumatology 
Division. NAORC brings together advanced 
research in rheumatology and orthopaedics, with 
the support and integration of large relational 
databases, clinical registries and biorepositories, 
information technology, and statistical support.
Scientists from UNMC are increasingly well 
positioned to investigate arthritis and disease 
epidemiology in arthritis. Together, the 
Department of Orthopaedics and the Division 
of Rheumatology account for thousands of 
outpatient visits annually at UNMC, providing 
referral services to a five state area in the 
Midwest. “NAORC has facilitated important 
Center’s Opening a 
great  milestone for 
research, education 
at UNMC
The Nebraska Arthritis Outcomes Research Center made 
possible by a major donation by Bill and Ruth Scott
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From left to right, Ted Mikuls, MD, 
MSPH, and Kaleb Michaud, PhD
examining the use of these novel drug delivery 
systems in treating joint replacement failure 
(loosening of implants) has been funded 
directly with NAORC-provided funding.
• The Benefits and Safety of Total Joint 
Replacement NAORC research efforts have 
demonstrated for the first time using meta-
analysis that shoulder replacement surgery 
leads to substantial improvement in overall 
quality of life for patients suffering from end-
stage shoulder arthritis. More recent efforts 
have focused on finding new ways of detecting 
infections impacting joint replacements and 
examining the impact and risk of procedures 
among those with rheumatoid arthritis.
• Links Between Oral Health and Arthritis 
NAORC researchers recently conducted the 
largest study ever completed demonstrating 
an association between gum disease with 
the risk of developing rheumatoid arthritis. 
The results suggest that treatments aimed 
at gum disease could play an important 
role in arthritis treatment and prevention.
• Novel Methods of Treating Gout As 
part of a NIH-funded program project 
grant, NAORC researchers are examining 
new ways of delivering gout care with 
the goal of improving outcomes in an 
often poorly managed condition.
• New Animal Models of Arthritis NAORC 
research efforts have for the first time led to 
the development of a new animal model for 
rheumatoid arthritis, one that more closely 
mimics human disease and that will be vital in 
examining new treatment paradigms in disease.
Attracting the Best and 
Brightest Researchers at 
UNMC and Elsewhere
• Collaborations of center researchers have 
expanded across the University of Nebraska 
system and now include: Dong Wang, PhD 
(UNMC College of Pharmacy); Kaihong Su, 
PhD (UNMC Department of Pathology); Jason 
(Zhixin) Zhang, PhD (UNMC Department of 
Pathology); Fang Yu, PhD (UNMC College 
of Public Health); and Jeffrey Payne, DDS 
(UNMC College of Dentistry), among others.
• National and international collaborations 
now include researchers at top-tier 
institutions in the U.S. (Stanford University, 
Johns Hopkins, Mayo Clinic, University 
of California San Francisco, and Harvard 
to name a few) in addition to arthritis 
research centers in Europe (Kennedy 
Institute in the U.K., the Karolinska 
Institute in Stockholm and others).
Building Support for State-of-
the-Art Arthritis Research 
• Registries and Biobanks NAORC leads the 
nation in the development of biorepositories 
and linked patient registries. These 
resources are vital in translating scientific 
discoveries into the arthritis clinic and serve 
as a research resource not only for UNMC 
investigators, but also for investigators both 
nationally and internationally. Efforts include 
the National Data Bank for Rheumatic 
Diseases (NDB), the VA Rheumatoid Arthritis 
Registry (VARA), the Rheumatology and  
Arthritis Investigational Network (RAIN) 
Database and, most recently, the Arthritis 
Internet Registry (AIR). NDB, RAIN, and 
AIR efforts have been led by Dr. Michaud 
with funding support from NAORC. NAORC 
support has allowed Dr. Michaud to develop 
and maintain links between registries 
and electronic health record data.
• FOCIS Center of Excellence Based on 
efforts to date, UNMC’s NAORC was 
designated a Federation of Clinical 
Immunology Societies (FOCIS) Center 
of Excellence. UNMC is one of only 62 
centers nationally with this recognition.
• State-of-the-Art Imaging in Arthritis 
NAORC researchers have developed 
and refined novel methods for precisely 
characterizing joint damage resulting as 
a consequence of arthritis. These efforts 
include the acquisition of state-of-the-art 
micro-CT scans (using predominantly NAORC 
funds) to characterize disease models 
in addition to the dynamic ultrasound in 
arthritis patients, a noninvasive approach 
that can be used in diagnosis and to 
guide therapeutic joint injections.
• Lupus Clinic Led by Dr. Michelene Hearth-
Holmes, NAORC faculty have established 
the new state-of-the-art Lupus Clinic in 
the Division of Rheumatology, a clinic 
that will serve as a vital resource for 
lupus researchers at UNMC. With this 
clinic as the foundation, UNMC now 
has a NIH-funded research portfolio 
in lupus and is participating in studies 
examining lupus treatments.
• Examining the Impact of Arthritis and 
its Treatment in U.S. Veterans NAORC 
has led efforts to expand clinical research 
programs to the Omaha VA, spearheading 
two large national cooperative studies 
examining arthritis treatment. Additional 
ongoing VA research includes the national 
VA Rheumatoid Arthritis Registry (VARA) 
and more recent efforts focused on 
improving the quality of gout care.
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Amy Cannella, MD, MS, sees exciting new 
educational opportunities for students and fellows. 
Dr. Cannella, fellowship director for the UNMC Division of Rheumatology, and her colleagues, are 
sharing that excitement, as well as dedication to their chosen field, with each group of internal 
medicine students, residents and fellows. 
Dr. Cannella described three major educational efforts in the division:
• The fellowship program with a 100 percent board pass rate;
• Education of the internal medicine residents;
• Medical student education (M2 and M3).
The division has two incoming fellows per year to complete a two-year fellowship at UNMC (with an 
option for a third year of research).
“These are very educationally oriented fellowships,” she said. “We have a lot of didactic teaching and 
a pretty intense curriculum that includes clinical rheumatology, musculoskeletal ultrasound and bone 
health.”
Fellows attend the American College of Rheumatology’s annual meeting, senior fellows go to the “state-
of-the-art” meeting, and senior fellows also participate in a national ultrasound curriculum—a new 
initiative that is part of the changing world of rheumatological education.
“Ultrasound has been increasingly picked up by many specialties,” Dr. Cannella said. “It shows us what 
the tissues look like under the skin. We can see if there’s pathology, and it can direct treatment. We can 
diagnose, treat, and educate patients in real time at the clinic visit.” 
Medical education: 
A fresh perspective 
“We can diagnose, 
treat, and educate 
patients in real time, 
at the clinic visit”
Amy Cannella, 
MD, MS
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From left to right: Amy Cannella, MD, MS, Rheumatology Fellowship Program Director, Brian 
Fay, MD, former fellow, Michelene Hearth-Holmes, MD, Jaclyn Anderson, DO, former 
fellow and Michael Feely, MD, former fellow Center front: Alan Erickson, MD
Musculoskeletal ultrasound also provides physicians with better information about the conditions they 
are seeking to treat.
“It’s good for patients to understand the pathophysiology of the disease,” Cannella said. 
“Rheumatologists are making decisions in real time about what’s going on in terms of the joint or the 
tissue. Patients love it.”
The rheumatology internal medicine resident training curriculum includes regular inpatient and 
outpatient teaching rounds, a distinct pre- and post-test evaluation, a computer-based x-ray and 
photographic case series and a didactic lecture series. Third year medical students may choose a 
rheumatology elective during their internal medicine clerkship, an opportunity not always available in 
other subspecialities.
“Residents and students also attend our didactic teaching sessions for the fellows,” Dr. Cannella said.
For the M2 musculoskeletal core, the division currently is redesigning the curriculum.
“We’re trying to flip the classroom,” she said. Efforts include a video game to teach about gout, live 
patients for medical students to interact with, more interactive, case-based activities and videotaped 
lectures students can watch on their own time.
“Students have changed, and have different learning needs and styles then when I was in the classroom,” 
Dr. Cannella said. “They don’t like to sit in lecture for hours—they want to do some things on their own 
and then come in and have the discussion.” 
“Rethinking medical education can be hard for some of us because medicine honors tradition. Ultimately, 
we want to be sensitive to our learners’ needs, while instilling the same work ethic, humility and passion 
for medicine that was passed down to us.”
From left to right: Anna Gramling, MD, 
Zachary Pruhs, MD, Amy Cannella, MD, MS, 
Leann Maska, MD, and Annika Cutinha, MD 
(former fellows)
“Students have 
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Alan Erickson, MD, 
serves as an “expert 
reader” of films 
for the Division of 
Rheumatology. 
Dr. Erickson joined the UNMC Division 
of Rheumatology in 2007 as a clinical 
rheumatologist, which remains 
the focus of his work today.
Thanks to James O’Dell, MD, who recognized 
Dr. Erickson’s deep interest in radiography, 
and the late John Sharp, MD, who mentored 
Dr. Erickson in the techniques of reading 
and scoring x-rays. Today he has rapidly 
become recognized as an “expert reader,” an 
essential part of such research efforts as the 
Rheumatoid Arthritis Comparison of Active 
Therapies (RACAT) trial and other studies like 
it, examining the effects of rheumatoid arthritis 
(RA) treatments. Along with Dr. Tim Moore 
from the UNMC Department of Radiology, Dr. 
Erickson read and scored films from the RACAT 
study, results that were published in the New 
England Journal of Medicine in July of 2013. 
In addition to reading films from the RACAT 
study and other national RA investigations, 
Dr. Erickson is reading films for the Veterans 
Affairs Rheumatoid Arthritis (VARA) registry, a 
large national cohort of U.S. veterans with RA.
“In a registry like the VARA registry, a lot of 
time we’re just looking at x-rays for one point in 
time,” Dr. Erickson said. “When we are trying 
to assess the severity of individual patients’ 
inflammatory arthritis, like RA, we want to 
know—Do they have evidence of joint damage? 
Do they have joint erosions and joint narrowing?”
As an expert reader of the radiographs, 
Dr. Erickson looks specifically for bony 
erosions and narrowing using a protocol 
that’s called the Modified Sharp Scoring 
Method—named after the physician mentor 
who taught the technique to Dr. Erickson.
“It’s a well-established radiographic assessment 
tool used in rheumatology to assess x-rays,” 
Dr. Erickson said. “I was fortunate enough 
to be taught the method by Dr. Sharp 
after he visited us at UNMC in 2007.”
Dr. Erickson spent several days working 
with Dr. Sharp to learn the basics. Dr. Sharp 
subsequently sent Dr. Erickson batches of x-rays 
to examine and score himself, so the two men 
could compare their notes and conclusions. 
“Most importantly, it’s about consistency. When 
readers look at x-rays, not everybody sees 
an erosion, not everybody sees narrowing—
there’s a degree of subjectivity to this.”
But consistency is paramount.
“Do you always call erosion erosion? Do you 
always call narrowing narrowing?” Dr. Erickson 
asked. “When I’m looking at an x-ray, and 
The reader
Alan Erickson, MD, scoring x-rays
then I’m looking at an x-ray taken 24 weeks 
later, we want to see if there are changes in 
the radiographs. It’s important that a change 
in the radiographs over time reflects a true 
change over time, not a variability based on 
whether or not I had a good night’s sleep.”
More recently, Dr. Erickson has assisted in 
research efforts including a study examining 
the relationship between severe gingivitis and 
RA led by Ted Mikuls, MD, MSPH, at UNMC. 
As part of this study, the team found that the 
presence of periodontitis (a severe form of 
gum disease) was associated with more x-ray 
damage among RA patients, findings that were 
recently published in Arthritis & Rheumatology.
‘’I act as a resource for Dr. Mikuls, Dr. 
Michaud, and Dr. O’Dell in their research 
trials,” Dr. Erickson said. “I fulfill a function 
that is necessary so that these registries can 
function the way they need to function, and the 
research trials can do what they need to do.”
Dr. Erickson is proud to be assisting in the 
Division of Rheumatology’s cutting edge research.
“These are important trials that are 
definitely affecting how we look at and 
treat rheumatoid arthritis,” he said. “It’s 
exciting to be a part of that.”
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Michelene Hearth-Holmes, MD, MEd from 
the Division of Rheumatology has made 
substantial strides in developing UNMC’s 
growing presence in research focused on 
systemic lupus erythematosus (SLE). She 
currently shares a close collaboration with 
Kaihong Su, PhD, Department of Pathology and 
Microbiology, on Dr. Su’s NIH-funded grant 
work examining novel biomarkers in SLE.
Dr. Hearth-Holmes’ role has been to act as the 
clinical conduit for this groundbreaking research, 
obtaining regulatory approvals, identifying a 
cohort of lupus patients from the UNMC Lupus 
Clinic that she directs, and tracking patients’ 
clinical data over the five-year study duration. 
Study participants are seen annually and when 
they have disease flares. Autoantibody tests are 
then administered by Dr. Su and her laboratory 
personnel to measure a novel biomarker 
she discovered called anti-NOD27 antibody. 
Circulating levels of this novel biomarker were 
found to be significantly elevated in patients 
with SLE compared to healthy control volunteers 
based on preliminary results from the study.
Dr. Hearth-Holmes said a very interesting 
aspect of the study, which occurred 
Lupus study becomes international affair
From left to right, Michelene Hearth-
Holmes, MD, MEd, and Kaihong 
Su, PhD, assessing patient
fortuitously, was a connection made with 
a clinician in the Dominican Republic, Dr. 
Esthela Loyo, at the Hospital Regional 
Universitario Jose Maria Cabral y Baez. 
Dr. Loyo’s son, who was doing a sub-internship 
at Creighton University, heard Dr. Su give a 
talk there. After the lecture, he told Dr. Su 
that his mother had many patients with 
lupus in the Dominican Republic where she 
practiced, and that he would speak to her 
about Dr. Su’s research. Collaborations took off 
from there. It turned out that Dr. Loyo follows 
about 300 patients with lupus, all Hispanic.
Although there are lupus patients all over the 
world, Dr. Hearth-Holmes said she did not 
realize there were so many from a single clinic 
alone in the Dominican Republic. Because 
they are all Hispanic, unique from most 
U.S. disease cohorts, this opens the doors 
for exploring even more questions focused 
on ethnic differences in disease expression. 
Consent forms and questionnaires have been 
translated into Spanish specifically for use in 
the Dominican Republic with patients enrolled 
in the UNMC-sponsored Rheumatology and 
Arthritis Investigational Network (RAIN) 
database. This database serves as a research 
resource to examine determinants of arthritis 
outcomes among patients with a variety of 
diagnoses. This will substantially expand the 
demographics of the RAIN database, which 
was developed almost 10 years ago and is now 
widely used among rheumatology researchers 
nationally and internationally. With extensions 
into the area of SLE and into the Dominican 
Republic and beyond, RAIN researchers continue 
to make progress in gaining important insights 
into arthritis and other autoimmune conditions.
Dr. Hearth-Holmes’ cross-continental work 
in support of SLE research is an important 
part of that progress. The collaboration 
with Dr. Loyo is just one example of how 
UNMC’s Division of Rheumatology is reaching 
across borders to research and battle 
lupus and other autoimmune diseases. 
Dr. Michelene Hearth-Holmes launches international lupus research study site.
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Lynell Klassen, MD, and Geoffrey Thiele, PhD
Lynell Klassen, MD, has spent a career 
grappling with one question: Why 
do people react to their own tissue?
“That’s a funny word—an immunological word—but what it really means is, 
why do people start reacting to their own tissues?” he says.
Sitting at a table in his office on the UNMC campus, he talks about his 
career: The early work at the National Institutes of Health, in what he 
calls “the dark ages” of the 1970s; the development of the Experimental 
Immunology Laboratory (EIL), currently being directed by his colleague, 
Geoffrey Thiele, PhD; and later, the studies of alcoholic liver disease he 
hoped would shed insight into environmental factors—specifically alcohol—
and how they affect autoimmune responses.
“People ask me, ‘What were you doing studying alcoholic liver disease as a 
rheumatologist who did bone marrow transplants?’” he says with a laugh. 
“There were opportunities at each institution I’ve been at, to use different 
model systems to look at this question—how do you lose self-tolerance or 
develop autoimmune disease?”
A rheumatologist, Dr. Klassen joined UNMC in 1982 and served as Vice 
Chair of Medicine and Chief of Rheumatology at UNMC, where he initiated 
the EIL, co-directed UNMC’s Bone Marrow Transplant Program and founded 
the HIV clinic. He served on the National Institutes of Health National 
Institute on Alcohol Abuse and Alcohol National Advisory Council. He also 
held key posts with the American College of Rheumatology and American 
College of Physicians (ACP).
Among his many awards, Dr. Klassen was inducted as a master of the 
ACP in 2011. In the 98-year history of the ACP, only a handful of other 
Nebraska physicians have received the master designation, which is given to 
physicians exhibiting preeminence in practice or medical research, holding 
positions of high honor or making significant contributions to medical 
science or the art of medicine. 
Currently, Dr. Klassen serves as Internal Medicine Chairman at UNMC and 
sees rheumatology patients in clinic one to two days a week.
But he still has time to wrestle with the research subject that has fascinated 
him since the beginning of his career. The classic disease example of loss 
of self-tolerance, he says, is systemic lupus erythematosus—the body reacts 
against itself destroying its own organ tissues. The question is, why does this 
happen to some people and not others?
Over the years, Dr. Klassen and his colleagues have studied a variety 
of different models to answer that question—a lupus animal model; 
The puzzle of 
‘the loss of self-tolerance’
examination of graft vs. host disease (GVHD), a consequence of bone 
marrow transplant; and studying the environmental effect of alcohol in 
causing the loss of self-tolerance.
From 2000-2010, his work earned him an NIH MERIT (Method to Extend 
Research in Time) Award for innovative studies in the role of immune 
responses in alcohol-associated tissue damage. He is one of only three 
UNMC researchers to ever receive the prestigious MERIT Award.
He continues to grapple with the puzzle of self-tolerance.
“There are several exciting things happening now,” he says. “First, it appears 
that there are certain patterns of antibody responses to the cell proteins 
that clearly differentiate people at risk for heart attacks, and heart disease. 
It appears that there are other antibody profiles that predispose people, or 
predict people who are going to get rheumatoid arthritis. 
“So why do you have this same reaction to a certain protein or piece of 
process; why does it look different in this disease process vs. that disease 
process?”
“There’s certainly a genetic base for that, and there’s certainly an 
environmental base for that,” he said. “So we’re trying to figure out where all 
of those things fit together.”
It’s a puzzle that’s lasted a professional lifetime—but Dr. Klassen is nowhere 
near ready to give up.
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Lynell Klassen, MD, and Geoffrey Thiele, PhD
Gerald Moore, MD, (far right) with students
A superlative internist, Dr. Gerald Moore’s biggest impact 
may be his legacy of committed and talented students. 
An icon in rheumatology
“He’s an icon in rheumatology,” Dr. Cannella said. 
“He’s an icon in medical education. He’s given 
his entire life to education. He brings a lot of 
enthusiasm, he is very practical in his approach 
to patient care, and he’s a wonderful teacher.”
A native of Lincoln, Dr. Moore graduated from 
Nebraska Wesleyan University in 1967 before 
advancing to UNMC, where he earned his MD 
in 1971. He has received more than $1 million in 
grant and contract funding for studies on medical 
education, but his interest in education is not 
simply academic. A long string of awards for 
his exemplary teaching skills include the LeeRoy 
Meyer Dedicated Teacher Award, presented 
in 2012 by the American College of Physicians 
(Nebraska Chapter); several UNMC Internal 
Medicine Top Teacher Awards, the most recent 
in 2010; the 2008 Hirshmann Golden Apple Prize 
(pre-clinical), awarded by the UNMC College of 
Medicine Class of 2008, and a slew of others.
A current fourth-year medical student, Marshall 
Davis, says Dr. Moore is a superlative instructor.
“He spends a lot of extra time individually with the 
students, especially in clinic,” Davis said. “We’d 
sit down and go through the case, and he’ll 
usually go through a few teaching points for each 
patient. Sometimes, when you work in groups, 
you don’t get that individualized attention – with 
Dr. Moore, that’s definitely there.”
Ted Mikuls, MD, MSPH, cites Dr. Moore— “a 
great rheumatologist with a foundation as a 
great internist” —as a major influence, not only 
on Dr. Mikuls, but on other senior faculty in the 
department, as well.
“As a student, there was never any ambiguity 
about expectations or feedback. As a student, 
if you don’t know where you stand with Dr. 
Moore, you probably need a hearing check,” Dr. 
Mikuls said. “What has set him apart from other 
instructors is his simultaneous respect for what 
many think of as ‘old school’ values in medicine—
like the central role of the history and the art of 
the physical exam—and how he has been able 
to successfully blend this with new technologies 
and other innovative ways to communicate with 
students across the spectrum of medical school 
training.”
Ask one former student about Gerald Moore, MD, 
and she’ll rattle off a rhyme.
“Small joint symmetrical synovitus means 
rheumatoid arthritis.”
“I can remember my lectures with him as a 
medical student,” said Amy Cannella, MD, MPH, 
now a colleague of Dr. Moore’s at UNMC. “Every 
time I see a patient with rheumatoid arthritis, I 
hear him in my head.”
From 1974, when he was the chief resident and 
an instructor at UNMC’s Department of Internal 
Medicine, to today, Dr. Moore has had an impact 
on medical education at UNMC. Today, Dr. 
Moore serves as the Senior Associate Dean for 
Academic Affairs for the College of Medicine and 
Professor in the Division of Rheumatology in the 
Department of Internal Medicine. 
As Senior Associate Dean, he oversees the 
College of Medicine admissions process, 
educational program for students and residents 
as well as faculty development issues. He has 
been an administrator in the College of Medicine 
for over 20 years, but continues to see patients in 
both Rheumatology Clinic as well as patients on 
the general internal medicine inpatient service.
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Ted Mikuls, MD, MSPH, is spearheading two efforts 
aimed at helping rheumatoid arthritis sufferers 
Registry, research offer
insights into RA risk factors
Dr. Mikuls, Professor of Internal Medicine, is 
spearheading two efforts that could make 
a big difference for the millions of people 
suffering with rheumatoid arthritis (RA): an 
examination of a possible cause of RA and a 
patient registry that continues to offer valuable 
insights into RA risk factors and outcomes.
The question of whether periodontal disease 
could be a cause of RA is the focus of 
research being done by investigators in 
the Division of Rheumatology at UNMC.
Led by Dr. Mikuls in collaboration with 
VA hospitals in Omaha, Dallas, Salt Lake 
City, and Washington D.C., the research 
initiative has enrolled 617 arthritis 
patients to take part in the study.
Several studies have shown statistical 
correlations between severe gum disease 
and RA. While correlation does not equate 
to causation, UNMC researchers are 
looking more closely at the issue.
“We’re assessing the possible role of different 
bacteria that live under the gums,” Dr. 
Mikuls said. “Early research from our group 
and others suggests that at least one 
of these bacterial species causing gum 
disease may trigger the early immunity 
that characterizes rheumatoid arthritis.”
But research for its own sake is not 
the point, Dr. Mikuls emphasizes. It is 
only a step toward the real goal.
“Who cares if we can say there’s this 
relationship?” Dr. Mikuls said. “That does 
not get us anywhere. The ultimate goal is 
to develop an intervention to treat or even 
prevent rheumatoid arthritis in the first place.”
This may involve better management of the 
bacteria that is present in a person’s gums or 
more effective cleaning methods. While those 
in the periodontal community are already 
working to develop advances in this area, any 
evidence linking RA to periodontal disease 
(PD) might help direct these advances.
In addition to studying those who contract 
RA, the study also looks at family members 
of patients who develop antibodies for the 
disease but don’t yet have the disease. This 
is part of how the study seeks to understand 
the early role of PD in the development 
of autoimmunity that leads to RA.
One result the UNMC researchers hope to 
achieve is a set of recommendations that 
would allow people to take proactive steps 
many years before they become susceptible 
to RA, as well as insight that can be helpful to 
those who are involved in periodontal care.
To address the aims of the study, an 
international multidisciplinary research team 
was gathered with extensive expertise in the 
epidemiology and immunology of RA and 
periodontitis and includes Dr. Jeffrey Payne 
from the UNMC College of Dentistry. The 
team’s access to important and highly unique 
patient populations will allow for the first 
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“The ultimate goal 
is to develop an 
intervention to treat 
or even prevent 
rheumatoid arthritis 
in the first place.”
Ted Mikuls, 
MD, MSPH
comprehensive examination of the association 
of PD and related bacterial infections with RA.
Dr. Mikuls also heads Veteran Affairs 
Rheumatoid Arthritis registry (VARA), a 
large national VA cohort of patients with RA, 
among the largest such in North America. 
The registry, created by Omaha VA and UNMC 
researchers, contains information about military 
veterans with RA. It may offer important 
insight into RA risk factors and outcomes 
in this highly unique patient population. 
More than 2 million Americans suffer from 
RA, and since females compose more than 
two-thirds of those with the disease, most 
research of the disease concerns females.
The veterans registry, VARA, stands to be an 
important source of information in the study 
of males with the disease, said Dr. Mikuls, who 
oversees the registry at the Omaha division of the 
VA Nebraska-Western Iowa Health Care System.
“While fewer men suffer from RA, that 
doesn’t discount the fact that men compose 
a significant portion of RA sufferers,” Dr. 
Mikuls said. “Because the veteran population 
is so overwhelmingly male, we are in a 
special position to gather information 
about men suffering from this disease.”
“Males account for almost 90 percent of the 
roughly 2,128 veterans with information 
in VARA—making it perhaps the nation’s 
top source of information about male 
RA sufferers,” Dr. Mikuls said.
Dr. Mikuls initiated VARA at the Omaha 
VA in 2003. The database contains clinical 
and biological information about the 
patients. VARA includes a large biorepository 
of DNA, serum, and patient plasma 
collected at the time of enrollment.
At first, information came just from local 
veterans with RA, but today VA medical centers 
in Birmingham, Brooklyn, Dallas, Denver, 
Iowa City, Jackson, Little Rock, Portland, 
Philadelphia, Salt Lake City and Washington, 
D.C., contribute information to the database.
In RA, the immune system promotes 
inflammation of the joints, leading to joint 
deformity and functional disability. 
Scientists know little about what causes 
RA, but most believe both genetics and the 
environment play a role in the disease.
The VARA registry allows researchers to examine 
specific medical and biological information 
about several thousand male RA sufferers to see 
what genetic and environmental factors may 
have played a role in the patients’ disease.
Leading RA scientists from around the nation, 
including Dr. James O’Dell from UNMC, 
have collaborated in research endeavors 
capitalizing on data collected in VARA.
“The vast amount of detailed information available 
to the database really makes this a critically 
important research resource,” said Dr. O’Dell.
From left to right: Alan Erickson, MD 
and Ted Mikuls, MD, MSPH 
9th annual VARA meeting hosted by UNMC 
Division of Rheumatology in the Sorrell Center
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Kaleb Michaud, PhD, 
is helping use 
technology and 
databases to better 
serve RA patients. 
Dr. Michaud isn’t afraid to think outside the 
box when it comes to using technology to 
better serve physicians and their patients.
He is working in collaboration with the 
American College of Rheumatology (ACR) 
on the Rheumatology Informatics System 
for Effectiveness (RISE) Registry, launched 
this year. The project’s long-term goal is to 
have all of the rheumatology clinics in the 
country enrolled and connected, providing a 
pool of electronic medical records available 
through the registry. UNMC Division of 
Rheumatology is one of the early adopters.
For academic centers, this can be tricky, Dr. 
Michaud said, because of the steps involved 
with institutional review boards, contracts and 
other considerations. “But in the end, the goal 
would be that any rheumatologist can quickly 
see how their patients or how their practice 
is doing compared to everybody else in the 
country,” he said. “So there’s that immediate 
feedback and quality improvement aspect.”
Dr. Michaud is an expert when it comes to 
databases. Since coming to the medical center in 
2007, he has become involved with the Veteran 
Affairs Rheumatoid Arthritis registry (VARA), the 
RAIN Database as its Principal Investigator, and 
as co-founder of the Arthritis Internet Registry 
(AIR). He also spends much of his time working 
and collaborating with others as Co-director 
of the National Data Bank for Rheumatic 
Diseases (NDB), the world’s largest patient-
reported research databank for rheumatic 
disorders, with more than 40,000 patients.
He is involved with many other projects and 
research at UNMC: he has a lead role in the 
Nebraska Arthritis Outcomes Research Center 
(NAORC), is a recipient of a new investigator 
award from the Arthritis Foundation to study the 
cost-effectiveness in total joint replacement in 
RA patients, received a NIH Challenge grant to 
investigate the cost-effectiveness of biological 
medications in RA treatment, and received an 
investigator award from the Rheumatology 
Research Foundation for assessing mortality in 
RA—but the RISE Registry has been an ongoing 
concern for Dr. Michaud. In fact, he was a 
member of the original subcommittees and task 
forces that helped create the fi rst phase of the 
project, the Rheumatology Clinical Registry. The 
resource still exists, in fact, and is used to collect 
data on many patients, but it doesn’t have any 
direct tie-in with their electronic medical records.
The RISE Registry could be utilized to 
address research questions, quantify which 
treatments and drugs are working and how 
well, and determined what rheumatologists 
From left to right:  Kaleb Michaud, PhD, and James O’Dell, MD
On the RISE
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are prescribing for certain conditions or 
sub-conditions—any number of uses.
“There’s a multitude of questions that can 
be asked,” Dr. Michaud said. “It has to start 
with actually having clinics connect.”
Dr. Michaud estimates that about 20 
clinics will be connected in 2014, with 
adoption picking up quickly.
“You can easily see this ramping up 
to 100 clinics in two years, and up to 
500 in three to five years,” he said.
With a multitude of measures for “quality” 
facing rheumatologists, from payers, national 
insurance, and the Centers for Medicare 
and Medicaid Services, the registry can help 
define what these measures should be.
“Payers and other organizations are constantly 
looking for new measures, especially measures 
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of Rheumatic 
Disease
said. “We need data to back up whether these 
measures are useful. No one wins when you 
have a rheumatologist who’s punished by an 
insurance company or a payer—because they 
see him as being too expensive or prescribing 
too many expensive treatments—but he actually 
has high-severity and more complicated 
patients compared to somebody else. The 
registry will provide data to back that up.”
With the registry, “we’re hoping to not have 
to measure things twice,” Dr. Michaud 
said. “Once it’s in the electronic medical 
record, you can just take it directly from 
there. That’s what RISE is all about.”
Yes, he admits, there is still work to do. But 
in the end, RISE will improve patient health, 
facilitate reporting requirements, and impact 
research that will advance rheumatology.
It’s a project on the RISE—and Dr. Michaud 
is one of the people who is helping lift it.
“We need data to 
back up whether 
these measures 
are useful... 
That’s what RISE 
is all about”
Kaleb Michaud, PhD
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Dr. James O’Dell and the Rheumatology and Arthritis Investigational Network 
have led UNMC to an international profile in RA research. 
As the leader of the Internal Medicine Residency 
Training Program for more than 30 years, 
Rheumatology Division Chief James O’Dell, MD, 
has directed the training of more than 600 
UNMC residents – researchers and physicians 
who will shape treatment in internal medicine 
and care of arthritis patients for years to come.
But Dr. O’Dell’s impact doesn’t stop 
there. He also is considered a pioneer in 
rheumatoid arthritis (RA) research.
Under Dr. O’Dell’s leadership, clinician-scientists 
at UNMC have garnered an international 
reputation in the treatment and research 
of RA. Since 1989, faculty members have 
repeatedly been responsible for breakthroughs 
in RA treatment – most notably pioneering 
the use of “Triple Therapy,” or combinations 
of disease-modifying medications to treat RA. 
Triple Therapy became popular in 1996 when 
UNMC and researchers from the Rheumatology 
and Arthritis Investigational Network (RAIN), 
led by Dr. O’Dell, published a landmark study 
in the New England Journal of Medicine.
RAIN has been critical to better understanding 
RA treatment at the patient level. Directed by 
Dr. O’Dell since its inception more than 20 
years ago, RAIN has become an internationally 
respected and productive investigator-initiated 
research network. The national consortium 
includes 40 rheumatologists in six states 
who participate in the design and enrollment 
of patients in clinical protocols. In addition, 
the first international site, in the Dominican 
Republic, began participating in RAIN in 2013.
RAIN was among the first to report correlations 
of treatment responses in RA with genes 
regulating the immune system. RAIN studies have 
also shown that a commonly used acne drug 
and antibiotic, minocycline, provided significant 
improvement for a subset of people with early RA. 
Dr. O’Dell, who also served as President of the 
American College of Rheumatology in 2012, was 
the principal investigator for the Rheumatoid 
Arthritis Comparison of Active Therapies (RACAT) 
trial. Funded by the Veterans Administration 
(VA), this $18 million study involved 16 VA sites, 
eight sites in Canada and 12 sites in the RAIN 
group, which included the Omaha VA Medical 
Center and UNMC. For the first time, the RA 
353-patient study combined a biorepository, 
and strong prospective economic data with 
a double-blind randomized clinical trial. 
James O’Dell, MD, with RA patient
The cooperative blinded study found that the 
use of less-expensive combination disease-
modifying anti-rheumatic drugs (DMARDs) 
produced the same clinical benefits as a 
much more-expensive biological treatment.
Results were published in the July 25, 2013 
edition of the New England Journal of Medicine.
“Before the study, there was a general belief 
that biologics have significantly more potency, 
but this study has proven that not to be 
the case in this patient population,” said Dr. 
O’Dell. “This study shows when conventional 
therapy is used before biologics, there should 
be a significant cost-savings not only to 
patients, but to the health care system.”
Dr. O’Dell said that one of the main reasons 
for the study is that the cost of treating RA 
has increased significantly and is now more 
expensive per patient than diabetes, primarily 
because of the use of biologic therapies. 
“We are looking for the safest and most effective 
medications,” Dr. O’Dell said. “The study shows 
that patients who start on the conventional 
combination therapy do just as well as people 
who start on a much more expensive therapy.”
RAIN man
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Study participant laughs with James O’Dell, MD, during a news conference at 
UNMC.  The patient participated in a study that showed a $1,000 rheumatoid 
arthritis treatment is as effective as a therapy that can cost over $20,000.
James O’Dell, MD, with RA patient
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“When I see patients, I know I have a lot of 
different treatment options to offer them. 
Twenty years ago that wasn’t the case. The 
prognosis for patients newly diagnosed 
with rheumatoid arthritis is excellent if 
therapy is started early,” Dr. O’Dell said.
Dr. O’Dell also co-authored one of the 
largest clinical studies ever done to prove RA 
patients can start on low cost monotherapy.  
The study was part of the Treatment of Early 
Aggressive Rheumatoid Arthritis (TEAR) trial, 
which received great international interest. Of 
755 patients in the 26-state study, 377 started 
on methotrexate alone and 28 percent did not 
need to be stepped up to another treatment. 
Other step-up treatments were a “combination” 
or “triple therapy” of methotrexate, sulfasalazine 
and hydroxychloroquine, or a biologic treatment 
of methotrexate plus etanercept. This was very 
signifi cant because the cost of triple therapy is 
less than $1,000 compared to the etanercept 
therapy cost of over $20,000 per year. Further, 
the potential for rare but serious toxicity has 
been a concern with the biological products.
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Background
Few blinded trials have compared conventional therapy consisting of a combination 
of disease-modifying antirheumatic drugs with biologic agents in patients with 
rheumatoid arthritis who have active disease despite treatment with methotrexate 
— a common scenario in the management of rheumatoid arthritis.
Methods
We conducted a 48-week, double-blind, noninferiority trial in which we randomly 
assigned 353 participants with rheumatoid arthritis who had active disease despite 
methotrexate therapy to a triple regimen of disease-modifying antirheumatic drugs 
(methotrexate, sulfasalazine, and hydroxychloroquine) or etanercept plus metho-
trexate. Patients who did not have an improvement at 24 weeks according to a pre-
specified threshold were switched in a blinded fashion to the other therapy. The 
primary outcome was improvement in the Disease Activity Score for 28-joint counts 
(DAS28, with scores ranging from 2 to 10 and higher scores indicating more dis-
ease activity) at week 48.
Results
Both groups had significant improvement over the course of the first 24 weeks 
(P = 0.001 for the comparison with baseline). A total of 27% of participants in each 
group required a switch in treatment at 24 weeks. Participants in both groups who 
switched therapies had improvement after switching (P<0.001), and the response 
after switching did not differ significantly between the two groups (P = 0.08). The 
change between baseline and 48 weeks in the DAS28 was similar in the two groups 
(−2.1 with triple therapy and −2.3 with etanercept and methotrexate, P = 0.26); triple 
therapy was noninferior to etanercept and methotrexate, since the 95% upper con-
fidence limit of 0.41 for the difference in change in DAS28 was below the margin 
for noninferiority of 0.6 (P = 0.002). There were no significant between-group differ-
ences in secondary outcomes, including radiographic progression, pain, and health-
related quality of life, or in major adverse events associated with the medications.
Conclusions
With respect to clinical benefit, triple therapy, with sulfasalazine and hydroxychlo-
roquine added to methotrexate, was noninferior to etanercept plus methotrexate in 
patients with rheumatoid arthritis who had active disease despite methotrexate 
therapy. (Funded by the Cooperative Studies Program, Department of Veterans Affairs 
Office of Research and Development, and others; CSP 551 RACAT ClinicalTrials.gov 
numbe , NCT00405275.)
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ACR and DAS28 Responses
There were no significant differences between the 
two groups in ACR 20 and ACR 50 responses at 
either 24 or 48 weeks (Table 2, and Fig. S4 in the 
Supplementary Appendix). A larger percentage of 
partic pants in he etanercept–methotrexate group 
had an ACR 70 response at 24 weeks, but the dif-
ference was not maint ined at 48 weeks. DAS28 
r sponses favor d etanercept–methotrexate ther-
apy at 24 weeks but did not differ significantly 
from those in the triple-therapy group at 48 weeks.
Radiographic Results
There was no significant difference between the 
two groups in radiographic progr ssion over 
the course of 48 w eks (Table 2). Participants in 
the triple-therapy group had a mean progression 
of 0.54 Sharp score units, and participants in the 
etanercept–methotrexate group had a mean pro-
gression of 0.29 Shar  score units (P = 0.43). Radio-
graphic progression as assessed on the basis of 
cumulative probability was not distinguishable be-
tween the two groups (Fig. S4 in the Supplemen-
tary Appendix).
Functional Outcomes
Both regimens resulted in clinically significant im-
provement in physical function (Table 2). All the 
articipa ts, regardless of whether they continued 
the initial therapy or switched at 24 weeks, had a 
significant improvement in the score on the health 
assessment questionnaire at the end of the trial 
(Table S3A in the Supplementary Appendix).
Adverse Events and Discontinuation  
of Medication
Table 3 shows the adverse events and serious ad-
verse events that were reported during the inter-
vention period and for 4 weeks after completion 
of the blinded intervention. Results are presented 
according to the therapy that the participant was 
receiving at the time of the event. After account-
ing for switching, 222 participants were exposed 
to triple therapy, and 219 to etanercept–metho-
trexate therapy. The frequencies of adverse events 
were similar in the two groups (Table S4 in the 
Supplementary Appendix). Gastrointestinal dis-
orders occurred more frequently with triple ther-
apy, whereas infections and skin and subcutane-
ous disorders occurred more frequently with 
etanercept–methotrexate therapy. A total of 17 
participants discontinued the intervention owing 
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Triple with switch to etanercept
Etanercept with switch to triple
Figure 1. Mean Scores on the DAS28.
Panel A shows the mean scores on the Disease Activity 
Score for 28-joint counts (DAS28, with scores ranging 
from 2 to 10 and higher cor s indicating more disease 
activity) according to the regimen to which the partici-
pants were randomly assigned at the beginning of the 
study. Triple therapy was noninferior to etanercept–
methotrexate therapy (P = 0.002). Panel B shows the 
me  scores according t  the thera i s received dur-
ing the course of the 48-week intervention period. Both 
groups of participants who switched therapies at 24 
weeks (represented by the top two curves: triple thera-
py to etanercept–methotrexate and etanercept–metho-
trexate to t iple therapy) had si nificant improvement 
after the switch (P<0.001 for each), with no significant 
difference in the amount of improvement (P = 0.08). In 
both panels, I bars indicate 95% confidence intervals.
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ACR and DAS28 Responses
There were no significant differences between the 
two groups in ACR 20 and ACR 50 responses at 
either 24 or 48 weeks (Table 2, and Fig. S4 in the 
Supplementary Appendix). A larger percentage of 
participants in the etanercept–methotrexate group 
had an ACR 70 response at 24 weeks, but the dif-
ference was not maintained at 48 weeks. DAS28 
responses favored etanercept–methotrexate ther-
apy at 24 weeks but did not differ significantly 
from those in the triple-therapy group at 48 weeks.
Radiographic Results
There was no significant difference between the 
two groups in radiographic progression over 
the course of 48 weeks (Table 2). Participants in 
the triple-therapy group had a mean progression 
of 0.54 Sharp score units, and participants in the 
etanercept–methotrexate group had a mean pro-
gression of 0.29 Sharp score units (P = 0.43). Radio-
graphic progression as assessed on the basis of 
cumulative probability was not distinguishable be-
tween the two groups (Fig. S4 in the Supplemen-
tary Appendix).
Functional Outcomes
Both regimens resulted in clinically significant im-
provement in physical function (Table 2). All the 
participants, regardless of whether they continued 
the initial therapy or switched at 24 weeks, had a 
significant improvement in the score on the health 
assessment questionnaire at the end of the trial 
(Table S3A in the Supplementary Appendix).
Adverse Events and Discontinuation  
of Medication
Table 3 shows the adverse events and serious ad-
verse events that were reported during the inter-
vention period and for 4 weeks after completion 
of the blinded intervention. Results are presented 
according to the therapy that the participant was 
receiving at the time of the event. After account-
ing for switching, 222 participants were exposed 
to triple therapy, and 219 to etanercept–metho-
trexate therapy. The frequencies of adverse events 
were similar in the two groups (Table S4 in the 
Supplementary Appendix). Gastrointestinal dis-
orders occurred more frequently with triple ther-
apy, whereas infections and skin and subcutane-
ous disorders occurred more frequently with 
etanercept–methotrexate therapy. A total of 17 
participants discontinued the intervention owing 
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Triple with switch to etanercept
Etanercept with switch to triple
Figure 1. Mean Scores on the DAS28.
Panel A shows the mean scores on the Disease Activity 
Score for 28-joint counts (DAS28, with scores ranging 
from 2 to 10 and higher scores indi ating mor  disease 
activity) according to the regimen to which the partici-
pa ts were randomly assigned at the beginning of the 
study. Triple therapy was noninferior to etanercept–
methotrexate therapy (P = 0.002). Panel B shows the 
m an scores according to the therapies received dur-
ing the course of the 48-week intervention period. Both 
groups of participants who switched therapies at 24 
weeks (represented by the top two curves: triple thera-
py to etanercept–methotrexate and etanercept–metho-
trexate to triple therapy) had significant improvement 
after the switch (P<0.001 for each), with no significant 
difference in the amount of improvement (P = 0.08). In 
both panels, I bars indicate 95% confidence intervals.
The New England Journal of Medicine 
Downl aded from nejm.org by JAMES ODELL on July 26, 2013. For personal use only. No other uses without permission. 
 Copy ight © 2013 Mass chusetts Medical Society. All rights reserved. 
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A top-tier 
team player
Dr. Thiele knows the importance of sharing his lab for a greater 
good. A career research scientist in the VA system, he directs the 
Experimental Immunology Laboratories (EIL) at the Omaha VA and 
UNMC, which have been existence since 1982. There, he leads efforts 
to link rheumatoid arthritis (RA) research with other disciplines.
He currently helps to direct the efforts of two national VA bio-repositories, 
including the Veteran Affairs Rheumatoid Arthritis (VARA) registry and 
the more recently developed Crystal Registry (a large, multicenter gout 
cohort from the VA). When specific studies are initiated, the EIL also runs 
many of the assays to evaluate the immune parameters associated with 
RA, such as Western blot, ELISA, immunohistochemistry and nephelometry.
Over the years, Dr. Thiele has collaborated with numerous 
UNMC faculty, notably in four specific areas of research:
• To study alcoholic liver disease, with Lynell Klassen, MD, Chair of the 
UNMC Department of Internal Medicine and a division faculty member
• To evaluate the relationship between periodontal 
disease and RA with Ted Mikuls, MD, MSPH
• To investigate the latest outcomes in RA studies with James O’Dell, MD
• To study the effects of the immune system in artherosclerosis in 
relation to RA with UNMC cardiologist Dan Anderson, MD, PhD
Dr. Geoffrey Thiele’s cross-
departmental collaborations link 
RA research with other disciplines. 
Geoffrey Thiele, PhD
From left to right: Karen Easterling, BA, Michael Duryee, MS, 
Anand Dusad, MD, and Bartlett Hamilton, III, BS
Recently, Dr. Thiele worked with a team of researchers – including 
cardiologist Dan Anderson, MD, PhD, on the discovery of a test that 
determines whether a patient has a lethal form of coronary artery 
disease by focusing on malondialdehyde-acetaldehyde (MAA), a molecule 
that appears to indicate the presence of coronary artery disease.
Dr. Thiele’s work includes a growing number of cross-departmental 
collaborations. Currently, Drs. Thiele and Mikuls have been 
working with Dong Wang, PhD, in the UNMC College of 
Pharmacy, studying nanoparticles as a new way of delivering anti-
inflammatory RA drugs at the site, rather than systemically.
Recently funded work with Kaihong Su, PhD, in the Department of 
Pathology and Microbiology, investigates the role of anti-neutrophil 
antibodies to initiated kidney damage in systemic lupus erythematous 
(SLE) using a precision—cut kidney slice model as target tissue. 
Additionally, studies with Laura Bilek, PhD, in the School of Allied 
Health Professions, have focused on the effects of exercise on the 
inflammatory markers in RA and resultant disease activity.
As a “seasoned scientist”, Dr. Thiele has played a key role in helping 
newer faculty and students in the division develop their interests 
in the rapidly expanding area of translational RA research.
“With the increased emphasis by the NIH and VA to perform research 
with higher clinical significance and translational potential, the 
studies performed by our group have generated the baseline data 
from which other investigators will be able to start,” said Dr. Thiele. 
“Because these samples have been well-characterized, an investigator 
can immediately perform studies asking more specific questions, 
allowing them to rapidly ask questions and get their answers.” 
Dr. Thiele’s many collaborative efforts have paved the way for a 
number of new investigations and studies at UNMC. His impact, 
and his work at EIL, transcends a single discipline—and the 
Division of Rheumatology is pleased to have him as a partner. 
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Selected Faculty Publications Feb. 2013 – Feb. 2014
• O’Dell, J.R., Mikuls, T.R., Taylor, T.H., Ahluwalia, 
V.A., Brophy, M., Warren, S.R, Lew, R.A., 
Cannella, A.C., Kunkel G., Phibbs, C.S., Anis, 
A.H., Leatherman S., Keystone E., CSP 551 
RACAT Investigators. (2013). Therapies for 
active rheumatoid arthritis after methotrexate 
failure, N Engl J Med, 369(4) 307-18.
• Mikuls, T.R., Payne, J.B., Yu, F., Thiele, G.M., 
Reynolds, R.J., Cannon, G.W., Markt, J., 
McGowan, D., Kerr, G.S., Redman, R.S., 
Reimold, A., Griffiths G., Beatty, M., Gonzalez, 
S., Bergman, D.A., Hamilton, B.C., Erickson, 
A.R., Sokolove, J. Robinson, W., Walker, C., 
Chandad, F., O’Dell, J.R. (2014). Periodontitis 
and porphyromonas gingivalis in Patients with 
Rheumatoid Arthritis. Arthritis Rheum, In Press
• Dusad, A., Duryee, M.J., Shaw, A.T., Klassen, 
L.W., Anderson, D.R., Wang, D., Ren, K., 
Gravallese, E.M., O’Dell, J.R., Mikuls, T.R., 
Thiele, G.M. (2014). Induction of bone loss 
in DBA/1J mice immunized with citrullinated 
autologous mouse type II collagen in the absence 
of adjuvant. Immunol Res, 58 (1) 51-60. 
• Quan, L., Zhang, Y., Crielaard, B.J., Dusad, 
A., Lele, S.M., Rijcken, C.J., Metselaar, J.M., 
Kostkova, H., Etrych, T., Ulbrich, K., Kiessling, 
F., Mikuls, T.R., Hennrick, W.E., Storm, G., 
Lammers, T., Wang, D. (2014). Nanomedicines for 
inflammatory arthritis: head-to-head comparison 
of glucocorticoid-containing polymers, micelles 
and liposomes. ACS Nano, 8 (1), 458-66.
• Cannella, A.C., Kissen, E.Y., Torralba, K.D., 
Higgs, J.B., Kaeley, G.S. (2014). Evolution of 
musculoskeletal ultrasound in the United 
States: implementation and practice in 
rheumatology. Arthritis Care Res, 66(1), 7-13.
• Michaud, K., Fehringer, E.V., Garvin, K., 
O’Dell, J.R., Mikuls, T.R. (2013). Rheumatoid 
arthritis patients are not at increased 
risk for 30-day cardiovascular events, 
infections, or mortality after total joint 
arthroplasty. Arthritis Res Ther, 15(6):R195.
• Carter, M.J., Mikuls, T.R., Nayak, S., Fehringer, 
E.V., Michaud, K. (2013). Impact of total 
shoulder arthroplasty on generic and shoulder-
specific health-related quality-of-life measures: 
a systematic literature review and meta-
analysis. J Bone Joint Surg Am, 94(17):e127.
• Dusad, A., Thiele, G.M., Klassen, L.W., Gleason, 
A.M., Bauer, C., Mikuls, T.R., Duryee, M.J., West, 
W.W., Romberger, D.J., Poole, J.A. (2013). Organic 
dust, lipopolysaccharide, and peptidoglycan 
inhalant exposures result in bone/loss/disease. 
Am J Respir Cell Mol Biol, 49(5), 829-36.
• Davis, M.L, Michaud, K., Sayles H., Conn, 
D.L., Moreland, L.W., Bridges, S.L. Jr, Mikuls, 
T.R. (2013).  Associations of alcohol use with 
radiographic disease progression in African 
Americans with recent-onset rheumatoid 
arthritis. J Rheumatol, 40(9), 1498-504.
• Young, K.A., Deane K.D., Derber, L.A., Hughes-
Austin, J.M., Wagner, C.A., Sokolove, J., Weisman, 
M.H., Buckner, J.H., Mikuls, T.R., O’Dell, J.R., 
Research Awards




the first Daughton 
Award for a non-faculty 
employee whose 
professional activities 
such as teaching, 
publications or scholarly research exceed what is 
normally expected of individuals in the position. The 
award was named for David Daughton, who had an 
exemplary career in the area of smoking cessation 
research and education in the Department.
Marshall Davis, M4 
received a Student 
Research Award for 
his initiative and 
exemplary work on his 
research project. Davis’ 
work resulted in two 
national presentations.
Bryant England, a 
current second year 
internal medicine 
resident at UNMC, 




from the Rheumatology 
Research Foundation. The project, mentored by 
Dr. Ted Mikuls in the Division of Rheumatology, 
will examine the role of both traditional and 
novel risk factors in predicting cardiovascular 
mortality in patients with rheumatoid arthritis.
Keating, R.M., Gregersen, P.K., Robinson, W.H., 
Holers, V.M., Norris, J.M. (2013). Relatives 
without rheumatoid arthritis show reactivity 
to anti-citrullinated protein/peptide antibodies 
that are associated with arthritis-related 
traits: studies of the etiology of rheumatoid 
arthritis. Arthritis Rheum, 65(8), 1995-2004. 
• O’Dell, J.R., Curtis, J.R., Mikuls, T.R., Cofield, 
S.S., Bridges, S.L. Jr, Ranganath, V.K., Cofield, 
S.S. (2013). Validation of the methotrexate-
first strategy in patients with early, poor-
prognosis rheumatoid arthritis: results 
from a two-year randomized, double-blind 
trial. Arthritis Rheum, 65(8), 1985-94. 
• Anderson, D.R., Poterucha, J.T., Mikuls, T.R., 
Duryee, M.J., Garvin R.P., Klassen, L.W., Shurmur, 
S.W., Thiele, G.M. (2013). Relationship between 
air pollution and positivity of RA-related 
autoantibodies in individuals with established RA: 
a report on SERA. Ann Rheum Dis, 72(12), 2002-5.
• Garg, R., Sayles, H.R., Yu, F., Michaud, K., 
Singh, J., Saag, K.G., Mikuls, T.R. (2013). 
Gout-related health care utilization in US 
emergency departments, 2006 through 
2008. Arthritis Care Res, 65(4), 571-7.
• Mikuls, T.R., Padala, P.R., Sayles, H.R., Yu, F., 
Michaud, K., Caplan, L., Kerr, G.S., Reimold, A., 
Cannon, G.W., Richards, J.S., Lazaro, D., Thiele, 
G.M., Boscarino, J.A. (2013). Prospective study 
of posttraumatic stress disorder and disease 
activity outcomes in US veterans with rheumatoid 
arthritis. Arthrits Care Res. 65(2), 227-34.
check out the 
Amazon bookstore 
to purchase a copy!
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UNMC and VA Rheumatology
and key collaborators impact the world!
